Skip to main content
Back
MDXG logo

MiMedx Group, Inc.

Data quality: 100%
Oversold
MDXG
NASDAQ Healthcare Biotechnology
$4.24
▲ $0.12 (2.91%)
Mkt Cap: 629.92M
Day Range
$4.22 $4.32
52-Week Range
$4.08 $8.12
Volume
763,270
50D / 200D Avg
$5.07 / $6.41
Prev Close
$4.12

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 13.0 0.4
P/B 2.5 2.9
ROE % 21.6 3.7
Net Margin % 11.6 3.8
Rev Growth 5Y % 14.7 10.0
D/E 0.1 0.2

Key Takeaways

Revenue grew 14.68% annually over 5 years — strong growth
ROE of 21.61% indicates high profitability
Debt/Equity of 0.09 — conservative balance sheet
Generating 72.97M in free cash flow
P/E of 12.97 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5.31%

Growth

Revenue Growth (5Y)
14.68%
Revenue (1Y)19.99%
Earnings (1Y)14.52%
FCF Growth (3Y)71.57%

Quality

Return on Equity
21.61%
ROIC17.17%
Net Margin11.60%
Op. Margin15.26%

Safety

Debt / Equity
0.09
Current Ratio4.32
Interest Coverage35.83

Valuation

P/E Ratio
12.97
P/B Ratio2.46
EV/EBITDA7.61
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19.99% Revenue Growth (3Y) 14.11%
Earnings Growth (1Y) 14.52% Earnings Growth (3Y) -15.13%
Revenue Growth (5Y) 14.68% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 418.63M Net Income (TTM) 48.58M
ROE 21.61% ROA 14.18%
Gross Margin 82.56% Operating Margin 15.26%
Net Margin 11.60% Free Cash Flow (TTM) 72.97M
ROIC 17.17% FCF Growth (3Y) 71.57%
Safety
Debt / Equity 0.09 Current Ratio 4.32
Interest Coverage 35.83 Dividend Yield 0.00%
Valuation
P/E Ratio 12.97 P/B Ratio 2.46
P/S Ratio 1.50 PEG Ratio 1.49
EV/EBITDA 7.61 Dividend Yield 0.00%
Market Cap 629.92M Enterprise Value 486.33M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 418.63M 348.88M 321.48M 267.84M 242.02M
Net Income 48.58M 42.42M 67.44M -30.20M -12.30M
EPS (Diluted) 0.32 0.28 0.38 -0.27 -0.09
Gross Profit 345.62M 288.81M 266.84M 219.53M 202.39M
Operating Income 63.89M 58.87M 37.12M -14.73M -7.05M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 342.65M 263.92M 239.05M 171.43M 187.93M
Total Liabilities 86.11M 70.81M 96.33M 96.92M 95.35M
Shareholders' Equity 256.55M 193.11M 142.72M 74.51M 92.58M
Total Debt 22.53M 24.84M 48.10M 52.47M 53.29M
Cash & Equivalents 166.12M 104.42M 82.00M 65.95M 87.08M
Current Assets 277.47M 191.89M 164.26M 134.20M 148.52M
Current Liabilities 64.27M 45.60M 46.01M 43.56M 42.36M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#610 of 1024
40
Value Value Investing (Warren Buffett)
#46 of 195
51

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Value Investing (Warren Buffett)
Mar 24, 2026